



Vivo Biosciences Inc.

Accelerating Preclinical Research, Drug Discovery & Therapeutics

NEWS RELEASE

Vivo Biosciences Presents at the 15th Annual Life Sciences Venture Forum

Birmingham, AL – July 13, 2009 – Vivo Biosciences presented at the recent 15th Annual Life Sciences Venture Forum in San Jose, CA on June 25, 2009. Vivo Biosciences joined fifteen other companies that were selected from the NIH sponsored LARTA Institute's Commercialization Assistance Program to showcase their promising technologies in the life sciences. Vivo Biosciences' President and Chief Executive Officer, Dr. Raj Singh delivered an oral presentation to the venture community highlighting new applications of the 3D HuBiogel™ assay platform in toxicology and oncology-focused personalized medicine. "The power of our 3D HuBiogel assay platform will benefit drug development companies' drug attrition rates by identifying compounds prone to toxicity at a preclinical stage. Multiple technologies are out there, but our platform is the only fully human in vitro assay system...all components including the ECM," said Dr. Singh. "Cells used in preclinical assays behave differently when placed in a 3D-human matrix system compared with animal-based matrices or directly on plastic culture plates. The HuBiogel system is more physiologically relevant than the others; therefore, its predictive power of pharmacodynamics is more relevant."

Vivo Biosciences' participation in the Life Sciences Venture Forum marks a culmination of its participation in the NIH-LARTA Institute's CAP program. The program has provided an excellent network of advisors and benchmarking information, and we are proud to be part of the valuable program.

About Vivo Biosciences, Inc.

Vivo Biosciences, Inc. is an emerging, venture-backed biotechnology company, incorporated in 2004 for the purpose of introducing a novel, human biomatrix, HuBiogel™, to the biological research markets. VBI strives to maximize the functional relevance & predictability of your cell-based assays. We are confident that our unique HuBiogel™ assays will improve drug efficacy/ toxicity endpoints and critical preclinical decisions.

About the HuBiogel™ Assay Platform

The 3D HuBiogel™ Assay Platform is a novel in vitro assay platform that recapitulates human cells in a fully human extracellular matrix. These three dimensional systems provide the drug development industry with a cost efficient assay to identify drug efficacy and toxicity. Current systems use animal based or synthetic extracellular matrices which may impact their in vivo predictability.

Vivo Biosciences' Contact: Lee T. Martin, Ph.D.

Source: Vivo Biosciences, Inc.

Vivo Biosciences Website: www.vivobiotech.com